Additionally, overexpression of immune checkpoints like CD274, PDCD1LG2, TIGIT, and SIGLEC15 in ccRCC with CASZ1-high expression suggests the importance of combining immune checkpoint biomarkers to predict ICI-based immunotherapy efficacy and guide potential multi-agent immunotherapy decisions. The gene discussed is SIGLEC15; the disease is nonpapillary renal cell carcinoma.